What changed today in Metabolic: 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records2 sources1 min read
Diabetes developments
Developments in type 2 diabetes care relevant to pharmacy and metabolic practice, including incretin therapies and cardiometabolic outcomes.
High attention
- Editorial attention
- High attention
- Tracked this week
- 17
- Sources this week
- 6
- Last activity
- 1 day ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Diabetes developments at a glance
- About this topic
- Developments in type 2 diabetes care relevant to pharmacy and metabolic practice, including incretin therapies and cardiometabolic outcomes.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Structured nutritional management of insulin resistance in women with PMOS (formerly PCOS) receiving GLP-1RA therapy (opens the source in a new tab) (Diabetes research and clinical practice, Nov 12, 2026)
- Key facts from tracked records
- 25 NPHLA briefings on this topic
What’s the latest on Diabetes developments?
25 totalWhat changed today in Metabolic: 4 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
What changed today in Metabolic: 13 trial updates, 2 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
What changed today in Metabolic: 5 trial updates, 1 new study
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
What changed today in Metabolic: 5 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records11 sources1 min read
What changed today in Metabolic: 4 new studies, 2 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
What changed today in Metabolic: 4 trial updates, 3 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
What changed today in Metabolic: 2 trial updates
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
What do the official records show?
Primary sources and peer-reviewed research- Structured nutritional management of insulin resistance in women with PMOS (formerly PCOS) receiving GLP-1RA therapy (opens the source in a new tab)
- Trial status changed to “Completed”: A Study of BGM0504 in Participants With Type 2 Diabetes (opens the source in a new tab)
Phase 3, BrightGene Bio-Medical Technology Co., Ltd.. Previously “Active, not recruiting”. Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: Drug: 5 mg BGM0504 Administered SC; Drug:10 mg BGM0504 Administered SC; Drug: Semaglutide Administered SC. Investigational: tr…
- New trial registered: AMBITION 3 (AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body…) (opens the source in a new tab)
Phase 3, Novo Nordisk A/S. Conditions: Type 2 Diabetes. Interventions: Zenagamtide; Semaglutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: AMBITION4 (A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared…) (opens the source in a new tab)
Phase 3, Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Interventions: Zenagamtide; Semaglutide; Placebo zenagamtide; Placebo semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- Trial status changed to “Recruiting”: A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes (opens the source in a new tab)
Phase 2, Hoffmann-La Roche. Previously “Active, not recruiting”. Conditions: Type 2 Diabetes Mellitus. Interventions: Tifeglipron; Semaglutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: SURPASS-EARLY (A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes) (opens the source in a new tab)
Phase 4, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Tirzepatide; Antihyperglycemic medication. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: CLEAR-GLP1 (24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the…) (opens the source in a new tab)
Not applicable, Portuguese Oncology Institute, Coimbra. Conditions: Retained Gastric Content; Delayed Gastric Emptying; Obesity; Type 2 Diabetes Mellitus (DM). Interventions: 24-Hour Clear Liquid Diet; Standard Fasting. Investigational: trial-stage therapies are not approved f…
- Results posted on ClinicalTrials.gov: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2… (opens the source in a new tab)
Phase 2, Eli Lilly and Company. Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Interventions: Retatrutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
Industry coverage
Headlines link to the original publication- STAT+: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug (opens the source in a new tab)
- Beyond Weight Loss: Survodutide's Cardiometabolic Effects (opens the source in a new tab)
- AHA 2026: Pharmacists at the Center of Cardiometabolic Care (opens the source in a new tab)
- GLP-1s' Effects on Cancer Risk May Be Influenced by Diabetes Severity (opens the source in a new tab)
- Wicked Good Cardiometabolic Chat: Ketone Monitoring in Pharmacy Practice (opens the source in a new tab)
- Early-Onset Colorectal Cancer; AI-Enabled Prior Auth; Type 1 Diabetes Subtypes (opens the source in a new tab)